AZN
AstraZeneca PLC
AZN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AZN overall, supported by stronger fundamentals and stronger modeled upside.
AZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Healthy |
AZN's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AZN PE Valuation
AZN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AZN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for AZN, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $6.66 | +25% |
| Q1 2026 | $6.64 | +52% |
| Q4 2025 | $6.54 | +68% |
| Q3 2025 | $6.02 | +70% |
| Q2 2025 | $5.31 | +51% |
| Q1 2025 | $4.36 | +7.4% |
| Q4 2024 | $3.89 | +1.8% |
| Q3 2024 | $3.54 | -6.6% |
AZN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $15.4B | +6.4% |
| Q1 2026 | $15.3B | +13% |
| Q4 2025 | $15.5B | +4.1% |
| Q3 2025 | $15.2B | +12% |
| Q2 2025 | $14.5B | +12% |
| Q1 2025 | $13.6B | +7.2% |
| Q4 2024 | $14.9B | +24% |
| Q3 2024 | $13.6B | +18% |
AZN's revenue has grown year over year for 13 quarters in a row: $15.4B last quarter, up 6.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | -3.7 points |
| Q1 2026 | 28% | +0.7 points |
| Q4 2025 | 19% | +5.5 points |
| Q3 2025 | 24% | +8.1 points |
| Q2 2025 | 24% | +3.1 points |
| Q1 2025 | 27% | +2.5 points |
| Q4 2024 | 14% | +3.4 points |
| Q3 2024 | 16% | -1.5 points |
AZN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AZN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.1B | +46% |
| Q1 2026 | $1.8B | -34% |
| Q4 2025 | $1.4B | -29% |
| Q3 2025 | $3.4B | +68% |
| Q2 2025 | $1.5B | -39% |
| Q1 2025 | $2.7B | +211% |
| Q4 2024 | $2B | +36% |
| Q3 2024 | $2B | -9.4% |
AZN generated $8.7B in free cash flow over the past year, up 6.8% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AZN on cash flow, with more consistent year-over-year improvement.
AZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -1M shares |
| 1 year | +0.1% | +1M shares |
| 3 years | 0% | -- |
| 5 years | +18% | +242M shares |
| Available history | +19% | +248M shares |
AZN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $46.3M |
| Q1 2026 | — |
| Q4 2025 | $198.8M |
| Q3 2025 | $12.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
AZN has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.3x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | 1.7x | Healthy |
AZN's net debt is about 1.3 years of its operating earnings (EBITDA), down from 1.5 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AZN on leverage, with a lower net debt burden relative to earnings.
AZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 85.9 | Overbought |
AZN's weekly RSI is 58 (neutral) and its Stochastic is 86 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AZN PE vs Healthcare Sector
| Metric | AZN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AZN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $172.1 | 7.1% above |
| 20 week MA | $169.4 | 8.9% above |
| 50 week MA | $181.2 | 1.8% above |
| 100 week MA | $165.1 | 12% above |
| 200 week MA | $153.4 | 20% above |
AZN is in an uptrend: it's above all five of its weekly moving averages, and 20% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
AZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $100.9 | $97.9 | -3% |
| 2021 | $97.9 | $115.0 | +18% |
| 2022 | $115.0 | $136.4 | +19% |
| 2023 | $136.4 | $134.4 | -1.4% |
| 2024 | $134.4 | $132.0 | -1.8% |
| 2025 | $132.0 | $181.3 | +37% |
| 2026 YTD | $181.3 | $184.4 | +1.7% |
AZN has finished lower in three of the last six years. It's up 1.7% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AZN on returns for 2026, with the stronger performance.